Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


How COVID unlocked the power of RNA vaccines

A staff member wearing a orange hi-vis jacket and hard har inspects a vaccines production line

Vaccine manufacturing facilities have had to rapidly ramp up their capabilities to produce RNA vaccines. Credit: Olivier Maire/EPA-EFE/Shutterstock

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature 589, 189-191 (2021)



  1. Geall, A. J. et al. Proc. Natl Acad. Sci. USA 109, 14604–14609 (2012).

    Article  PubMed  Google Scholar 

  2. Hekele, A. et al. Emerg. Microbes Infect. 2, e52 (2013).

    Article  PubMed  Google Scholar 

  3. Ulmer, J. B., Mansoura, M. K. & Geall, A. J. Expert Opin. Drug Discov. 10, 101–106 (2015).

    Article  PubMed  Google Scholar 

  4. Martinon, F. et al. Eur. J. Immunol. 23, 1719–1722 (1993).

    Article  PubMed  Google Scholar 

  5. Alberer, M. et al. Lancet 390, 1511–1520 (2017).

    Article  PubMed  Google Scholar 

  6. Feldman, R. A. et al. Vaccine 37, 3326–3334 (2019).

    Article  PubMed  Google Scholar 

  7. Freyn. A. W. et al. Mol. Ther. 28, 1569–1584 (2020).

    Article  PubMed  Google Scholar 

  8. Zhang, N.-N. et al. Cell 182, 1271–1283 (2020).

    Article  PubMed  Google Scholar 

  9. Beissert, T. et al. Mol. Ther. 28, 119–128 (2020).

    Google Scholar 

Download references


Latest on:

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links